person · Reporting owner

HENNEMAN JOHN B III

Disclosed activity across 7 companies

Tapewire entity: 36126
SEC CIK: 0001187572

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Anika Therapeutics, Inc.ANIK · Entity 6005	Director	June 18, 2026	June 23, 2026
Aprea Therapeutics, Inc.APRE · Entity 7948	Director	June 16, 2026	June 17, 2026
LUMOS PHARMA, INC.(NLNK) · Entity 85102	Chief Administrative Officer	October 01, 2018	October 02, 2018
Orthofix Medical Inc.OFIX · Entity 1975	Director	June 10, 2026	June 12, 2026
R1 RCM Holdco Inc.NONE · Entity 125898	Director	June 21, 2022	June 24, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Anika Therapeutics, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	65,273	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Grant · Acquired 10,402 · Balance 65,273 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

Aprea Therapeutics, Inc.

Report date June 16, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,364	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 3,135 · Balance 13,364 F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2036-06-16	Direct	12,555	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Grant · Acquired 12,555 · Balance 12,555 F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

LUMOS PHARMA, INC.

Report date October 01, 2018 · Filed October 02, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	55,052	Reported balance After 2018-10-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-10-01 · Tax withholding · Disposed 2,484 · Balance 55,052 F1: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 10,198 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 10,198 previously reported restricted stock units ("RSUs") granted to the Reporting Person.

F2: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

F3: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Orthofix Medical Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	105,774	Reported balance After 2026-06-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 105,774 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 48,347 previously reported deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.

F2: Includes 48,347 previously reported deferred stock units.

R1 RCM Holdco Inc.

Report date June 21, 2022 · Filed June 24, 2022

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-06-21 transaction · row 1 1 source row Row 1 · 2022-06-21 · Disposition to issuer · Disposed 54,751 · Balance 0 F1: On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger, dated as of January 9, 2022, by and among R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.) (the "Company"), R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.) ("New R1"), Project Roadrunner Merger Sub Inc. ("R1 Merger Sub"), CoyCo 1, L.P., CoyCo 2, L.P. and certain other parties, R1 Merger Sub was merged with and into the Company, with the Company surviving as a direct, wholly owned subsidiary of New R1 (the "Reorganization"). F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2026-02-22	Direct	Reported balance After 2022-06-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-21 · Disposition to issuer · Disposed 405,111 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F3: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.53 · Expires 2026-04-01	Direct	Reported balance After 2022-06-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-06-21 · Disposition to issuer · Disposed 12,048 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2026-07-01	Direct	Reported balance After 2022-06-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-06-21 · Disposition to issuer · Disposed 15,385 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2026-10-03	Direct	Reported balance After 2022-06-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-06-21 · Disposition to issuer · Disposed 13,762 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2027-01-03	Direct	Reported balance After 2022-06-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-06-21 · Disposition to issuer · Disposed 14,098 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2027-04-03	Direct	Reported balance After 2022-06-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-06-21 · Disposition to issuer · Disposed 10,512 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2027-07-03	Direct	Reported balance After 2022-06-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-06-21 · Disposition to issuer · Disposed 9,678 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2027-10-02	Direct	Reported balance After 2022-06-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-06-21 · Disposition to issuer · Disposed 9,169 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2028-01-02	Direct	Reported balance After 2022-06-21 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-06-21 · Disposition to issuer · Disposed 7,697 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-04-02	Direct	Reported balance After 2022-06-21 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-06-21 · Disposition to issuer · Disposed 4,770 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2028-07-02	Direct	Reported balance After 2022-06-21 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-06-21 · Disposition to issuer · Disposed 3,871 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.01 · Expires 2028-10-01	Direct	Reported balance After 2022-06-21 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-06-21 · Disposition to issuer · Disposed 3,319 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2029-01-02	Direct	Reported balance After 2022-06-21 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-06-21 · Disposition to issuer · Disposed 4,285 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.57 · Expires 2029-04-01	Direct	Reported balance After 2022-06-21 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-06-21 · Disposition to issuer · Disposed 3,684 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2029-07-01	Direct	Reported balance After 2022-06-21 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-06-21 · Disposition to issuer · Disposed 2,846 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2029-10-01	Direct	Reported balance After 2022-06-21 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2022-06-21 · Disposition to issuer · Disposed 4,025 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.69 · Expires 2030-01-02	Direct	Reported balance After 2022-06-21 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2022-06-21 · Disposition to issuer · Disposed 2,851 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.41 · Expires 2030-04-01	Direct	Reported balance After 2022-06-21 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2022-06-21 · Disposition to issuer · Disposed 4,542 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.75 · Expires 2030-05-28	Direct	Reported balance After 2022-06-21 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2022-06-21 · Disposition to issuer · Disposed 30,813 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F3: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.78 · Expires 2030-07-01	Direct	Reported balance After 2022-06-21 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2022-06-21 · Disposition to issuer · Disposed 3,249 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.54 · Expires 2030-10-01	Direct	Reported balance After 2022-06-21 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2022-06-21 · Disposition to issuer · Disposed 2,186 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.49 · Expires 2031-01-04	Direct	Reported balance After 2022-06-21 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2022-06-21 · Disposition to issuer · Disposed 1,625 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.98 · Expires 2031-04-01	Direct	Reported balance After 2022-06-21 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2022-06-21 · Disposition to issuer · Disposed 1,490 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.46 · Expires 2031-07-01	Direct	Reported balance After 2022-06-21 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2022-06-21 · Disposition to issuer · Disposed 1,660 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F5: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on July 1, 2022.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2031-10-01	Direct	Reported balance After 2022-06-21 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2022-06-21 · Disposition to issuer · Disposed 1,649 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F6: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on October 1, 2022.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.70 · Expires 2032-01-03	Direct	Reported balance After 2022-06-21 transaction · row 27 Instrument identity requires review; Table II rows are not merged. 1 source row Row 27 · 2022-06-21 · Disposition to issuer · Disposed 1,424 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F7: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on January 3, 2023.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.69 · Expires 2032-04-01	Direct	Reported balance After 2022-06-21 transaction · row 28 Instrument identity requires review; Table II rows are not merged. 1 source row Row 28 · 2022-06-21 · Disposition to issuer · Disposed 1,965 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F8: Option was granted in lieu of retainer fees of $22,500 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on April 1, 2023.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-06-21 transaction · row 29 Instrument identity requires review; Table II rows are not merged. 1 source row Row 29 · 2022-06-21 · Disposition to issuer · Disposed 6,039 · Balance 0 F9: Each RSU represents a contingent right to receive one share of the Company's common stock. F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F10: The RSUs will vest in one annual installment on May 27, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger, dated as of January 9, 2022, by and among R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.) (the "Company"), R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.) ("New R1"), Project Roadrunner Merger Sub Inc. ("R1 Merger Sub"), CoyCo 1, L.P., CoyCo 2, L.P. and certain other parties, R1 Merger Sub was merged with and into the Company, with the Company surviving as a direct, wholly owned subsidiary of New R1 (the "Reorganization").

F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization.

F3: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.

F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.

F5: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on July 1, 2022.

F6: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on October 1, 2022.

F7: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on January 3, 2023.

F8: Option was granted in lieu of retainer fees of $22,500 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on April 1, 2023.

F9: Each RSU represents a contingent right to receive one share of the Company's common stock.

F10: The RSUs will vest in one annual installment on May 27, 2023.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

R1 RCM Inc. /DE

Report date November 19, 2024 · Filed November 19, 2024

Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-11-19 transaction · row 1 1 source row Row 1 · 2024-11-19 · Disposition to issuer · Disposed 87,765 · Balance 0 F1: Pursuant to and in connection with the transactions contemplated by that certain Agreement and Plan of Merger (the "Merger Agreement"), dated July 31, 2024, by and among the Issuer, Raven Acquisition Holdings, LLC ("Parent") and Project Raven Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), at the time of the Merger (the "Effective Time") the reported securities were disposed of, with 72,114 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), cancelled and converted into the right to receive $14.30 per share in cash without interest (the "Merger Consideration"). F2: Represents 15,651 shares of Common Stock of the Issuer underlying restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such RSUs as of immediately prior to the Effective Time and (b) the Merger Consideration.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-11-19 · Disposition to issuer · Disposed 515,715 · Balance 0 F3: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to and in connection with the transactions contemplated by that certain Agreement and Plan of Merger (the "Merger Agreement"), dated July 31, 2024, by and among the Issuer, Raven Acquisition Holdings, LLC ("Parent") and Project Raven Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), at the time of the Merger (the "Effective Time") the reported securities were disposed of, with 72,114 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), cancelled and converted into the right to receive $14.30 per share in cash without interest (the "Merger Consideration").

F2: Represents 15,651 shares of Common Stock of the Issuer underlying restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such RSUs as of immediately prior to the Effective Time and (b) the Merger Consideration.

F3: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time.

SeaSpine Holdings Corp

Report date January 05, 2023 · Filed January 10, 2023

Section 16 reporting ended · disclosed 2023-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-01-05 transaction · row 1 1 source row Row 1 · 2023-01-05 · Disposition to issuer · Disposed 82,654 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 34,408 Orthofix MedicalInc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.68 · Expires 2025-08-01	Direct	Reported balance After 2023-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-05 · Disposition to issuer · Disposed 58,559 · Balance 0 F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 24,378 shares of Orthofix at a price of $37.67 per share. F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.18 · Expires 2026-01-01	Direct	Reported balance After 2023-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-05 · Disposition to issuer · Disposed 3,858 · Balance 0 F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 1,606 shares of Orthofix at a price of $41.27 per share. F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2026-06-07	Direct	Reported balance After 2023-01-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-05 · Disposition to issuer · Disposed 13,920 · Balance 0 F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 5,794 shares of Orthofix at a price of $24.00 per share. F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 34,408 Orthofix MedicalInc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.

F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.

F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 24,378 shares of Orthofix at a price of $37.67 per share.

F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.

F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 1,606 shares of Orthofix at a price of $41.27 per share.

F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 5,794 shares of Orthofix at a price of $24.00 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jun 23, 2026 20:30 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	GrantCommon Stock	10,402	$0.00	$0.00	Disclosure SEC source: 0001193125-26-279542 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,273 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027. Read SEC document
June 16, 2026 Filed Jun 17, 2026 23:05 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Options (Right to Buy) · Derivative	12,555	$0.00 Strike: $0.73	$0.00	Disclosure SEC source: 0001104659-26-075282 · tm2618211-5_4seq1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,555 Underlying: Common Stock · 12,555 shares Expires 2036-06-16 F2 · derivative.exercise_date: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 16, 2026 Filed Jun 17, 2026 23:05 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantCommon Stock	3,135	$0.00	$0.00	Disclosure SEC source: 0001104659-26-075282 · tm2618211-5_4seq1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,364 F1 · shares: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 10, 2026 Filed Jun 12, 2026 22:27 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	14,965	$0.00	$0.00	Disclosure SEC source: 0001193125-26-269865 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,774 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 48,347 previously reported deferred stock units. Read SEC document
May 07, 2026 Filed May 8, 2026 20:52 UTC	Orthofix Medical Inc. OFIX · Entity 1975	PurchaseCommon Stock	5,000	$12.26	$61,295.00	Disclosure SEC source: 0001193125-26-214850 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,809 F1 · balance_after: Includes 48,347 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document
May 01, 2026 Filed May 4, 2026 12:34 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	PurchaseCommon Stock	5,000	$14.66	$73,319.50	Disclosure SEC source: 0001193125-26-202704 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,871 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.595 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 20, 2025 Filed Jun 24, 2025 21:06 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	GrantCommon Stock	14,164	$0.00	$0.00	Disclosure SEC source: 0001171843-25-004067 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,871 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:15 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	18,841	$0.00	$0.00	Disclosure SEC source: 0000950170-25-088989 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,706 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 29,506 previously reported deferred stock units and 951 shares acquired under Orthofix's Stock Purchase Plan on 4/30/2025. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:05 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Options (Right to Buy) · Derivative	4,185	$0.00 Strike: $1.81	$0.00	Disclosure SEC source: 0001104659-25-057815 · tm2517366-5_4seq1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2035-06-05 F2 · derivative.exercise_date: The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:05 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantCommon Stock	1,045	$0.00	$0.00	Disclosure SEC source: 0001104659-25-057815 · tm2517366-5_4seq1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,229 F1 · shares: These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
November 19, 2024 Filed Nov 19, 2024 22:35 UTC	R1 RCM Inc. /DE RCM · Entity 85753	Disposition to issuerDirector Stock Option (right to buy) · Derivative	515,715	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-128856 · ownership.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 515,715 shares Expires not disclosed F3 · derivative.exercise_price: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time. F3 · kind: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time. F3 · price: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time. F3 · derivative.exercise_date: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time. F3 · derivative.expiration_date: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time. Read SEC document
November 19, 2024 Filed Nov 19, 2024 22:35 UTC	R1 RCM Inc. /DE RCM · Entity 85753	Disposition to issuerCommon Stock	87,765	$14.30	$1,255,039.50	Disclosure SEC source: 0000950170-24-128856 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to and in connection with the transactions contemplated by that certain Agreement and Plan of Merger (the "Merger Agreement"), dated July 31, 2024, by and among the Issuer, Raven Acquisition Holdings, LLC ("Parent") and Project Raven Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), at the time of the Merger (the "Effective Time") the reported securities were disposed of, with 72,114 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), cancelled and converted into the right to receive $14.30 per share in cash without interest (the "Merger Consideration"). F2 · kind: Represents 15,651 shares of Common Stock of the Issuer underlying restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such RSUs as of immediately prior to the Effective Time and (b) the Merger Consideration. F1 · acquired: Pursuant to and in connection with the transactions contemplated by that certain Agreement and Plan of Merger (the "Merger Agreement"), dated July 31, 2024, by and among the Issuer, Raven Acquisition Holdings, LLC ("Parent") and Project Raven Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), at the time of the Merger (the "Effective Time") the reported securities were disposed of, with 72,114 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), cancelled and converted into the right to receive $14.30 per share in cash without interest (the "Merger Consideration"). F2 · acquired: Represents 15,651 shares of Common Stock of the Issuer underlying restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such RSUs as of immediately prior to the Effective Time and (b) the Merger Consideration. Read SEC document
July 09, 2024 Filed Jul 11, 2024 20:33 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	GrantCommon Stock	5,771	$0.00	$0.00	Disclosure SEC source: 0001171843-24-003906 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,707 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:17 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Options (Right to Buy) · Derivative	4,185	$0.00 Strike: $4.07	$0.00	Disclosure SEC source: 0001104659-24-073941 · tm2417666-3_4seq1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2034-06-20 F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:17 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantCommon Stock	1,045	$0.00	$0.00	Disclosure SEC source: 0001104659-24-073941 · tm2417666-3_4seq1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,184 F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 18, 2024 Filed Jun 20, 2024 11:04 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	15,152	$12.87	$195,006.24	Disclosure SEC source: 0000950170-24-075301 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,914 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 29,506 deferred stock units. Read SEC document
May 23, 2024 Filed May 23, 2024 23:44 UTC	R1 RCM Inc. /DE RCM · Entity 85753	GrantCommon Stock	15,651	$0.00	$0.00	Disclosure SEC source: 0001628280-24-025050 · wk-form4_1716507844.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,765 F1 · shares: Represents restricted stock units ("RSUs") issued to the reporting person that will vest on May 23, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document
March 13, 2024 Filed Mar 15, 2024 00:52 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	PurchaseTranche B Warrant · Derivative	3,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-034671 · tm248935-2_4seq1.xml · derivative · entry 3 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share. F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. Read SEC document
March 13, 2024 Filed Mar 15, 2024 00:52 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	PurchaseTranche A Warrant · Derivative	3,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-034671 · tm248935-2_4seq1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share. F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. Read SEC document
March 13, 2024 Filed Mar 15, 2024 00:52 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	PurchaseCommon Stock	6,860	$7.29	$50,009.40	Disclosure SEC source: 0001104659-24-034671 · tm248935-2_4seq1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,139 Read SEC document
August 23, 2023 Filed Aug 25, 2023 01:51 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Options (Right to Buy) · Derivative	2,000	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001104659-23-095019 · tm2324788-6_4seq1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2033-08-23 F2 · derivative.exercise_date: The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
August 23, 2023 Filed Aug 25, 2023 01:51 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantCommon Stock	500	$0.00	$0.00	Disclosure SEC source: 0001104659-23-095019 · tm2324788-6_4seq1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279 F1 · shares: These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
August 08, 2023 Filed Aug 9, 2023 20:36 UTC	R1 RCM Inc. /DE RCM · Entity 85753	Exercise / conversionDirector Stock Option (right to buy) · Derivative	50,000	$0.00 Strike: $2.61	$0.00	Disclosure SEC source: 0001628280-23-028615 · wf-form4_169161340135900.xml · derivative · entry 3 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,111 Underlying: Common Stock · 50,000 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
August 08, 2023 Filed Aug 9, 2023 20:36 UTC	R1 RCM Inc. /DE RCM · Entity 85753	SaleCommon Stock	50,000	$17.17	$858,650.00	Disclosure SEC source: 0001628280-23-028615 · wf-form4_169161340135900.xml · nonDerivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,114 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.135 to $17.24 per share. The reporting person undertakes to provide to R1 RCM Inc., any security holder of R1 RCM Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
August 08, 2023 Filed Aug 9, 2023 20:36 UTC	R1 RCM Inc. /DE RCM · Entity 85753	Exercise / conversionCommon Stock	50,000	$2.61	$130,500.00	Disclosure SEC source: 0001628280-23-028615 · wf-form4_169161340135900.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:16 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	GrantCommon Stock	6,500	$0.00	$0.00	Disclosure SEC source: 0001171843-23-003959 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,936 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. Read SEC document
May 18, 2023 Filed May 19, 2023 23:01 UTC	R1 RCM Inc. /DE RCM · Entity 85753	GrantCommon Stock	11,324	$0.00	$0.00	Disclosure SEC source: 0001628280-23-019151 · wf-form4_168453727320782.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,114 F1 · shares: Represents restricted stock units ("RSUs") issued to the reporting person that will vest on May 18, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:03 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	14,052	$0.00	$0.00	Disclosure SEC source: 0001209191-23-002654 · doc4.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,460 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the first anniversary of the grant date, January 5, 2023. F2 · balance_after: Includes 14,052 deferred stock units. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:19 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerStock Option (right to buy) · Derivative	13,920	Not disclosed Strike: $9.99	Not disclosed	Disclosure SEC source: 0001637761-23-000041 · wf-form4_167330996349891.xml · derivative · entry 4 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,920 shares Expires 2026-06-07 F7 · price: This option was assumed by Orthofix in the merger and replaced with an option to purchase 5,794 shares of Orthofix at a price of $24.00 per share. F6 · derivative.exercise_date: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:19 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerStock Option (right to buy) · Derivative	3,858	Not disclosed Strike: $17.18	Not disclosed	Disclosure SEC source: 0001637761-23-000041 · wf-form4_167330996349891.xml · derivative · entry 3 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,858 shares Expires 2026-01-01 F5 · price: This option was assumed by Orthofix in the merger and replaced with an option to purchase 1,606 shares of Orthofix at a price of $41.27 per share. F4 · derivative.exercise_date: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:19 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerStock Option (right to buy) · Derivative	58,559	Not disclosed Strike: $15.68	Not disclosed	Disclosure SEC source: 0001637761-23-000041 · wf-form4_167330996349891.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,559 shares Expires 2025-08-01 F3 · price: This option was assumed by Orthofix in the merger and replaced with an option to purchase 24,378 shares of Orthofix at a price of $37.67 per share. F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:19 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerCommon Stock	82,654	Not disclosed	Not disclosed	Disclosure SEC source: 0001637761-23-000041 · wf-form4_167330996349891.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 34,408 Orthofix MedicalInc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger. Read SEC document
January 05, 2023 Filed Feb 9, 2023 22:57 UTC Amendment	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	14,354	$0.00	$0.00	Disclosure SEC source: 0001209191-23-008128 · doc4a.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,762 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2 · shares: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3 · balance_after: Includes 14,354 deferred stock units. Read SEC document
July 28, 2022 Filed Aug 1, 2022 21:03 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Option (right to Buy) · Derivative	29,575	$0.00 Strike: $1.09	$0.00	Disclosure SEC source: 0001104659-22-084765 · tm2222147-5_4seq1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,575 Underlying: Common Stock · 29,575 shares Expires 2032-07-28 F2 · derivative.exercise_date: The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
July 28, 2022 Filed Aug 1, 2022 21:03 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantCommon Stock	5,995	$0.00	$0.00	Disclosure SEC source: 0001104659-22-084765 · tm2222147-5_4seq1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,605 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerRestricted Stock Units · Derivative	6,039	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 29 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,039 shares Expires not disclosed F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F10 · derivative.exercise_date: The RSUs will vest in one annual installment on May 27, 2023. F10 · derivative.expiration_date: The RSUs will vest in one annual installment on May 27, 2023. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	1,965	Not disclosed Strike: $26.69	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 28 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,965 shares Expires 2032-04-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F8 · derivative.exercise_date: Option was granted in lieu of retainer fees of $22,500 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on April 1, 2023. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	1,424	Not disclosed Strike: $25.70	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 27 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,424 shares Expires 2032-01-03 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F7 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on January 3, 2023. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	1,649	Not disclosed Strike: $22.57	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 26 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,649 shares Expires 2031-10-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F6 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on October 1, 2022. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	1,660	Not disclosed Strike: $22.46	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 25 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,660 shares Expires 2031-07-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F5 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on July 1, 2022. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	1,490	Not disclosed Strike: $24.98	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 24 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,490 shares Expires 2031-04-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	1,625	Not disclosed Strike: $23.49	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 23 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,625 shares Expires 2031-01-04 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	2,186	Not disclosed Strike: $17.54	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 22 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,186 shares Expires 2030-10-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	3,249	Not disclosed Strike: $11.78	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 21 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,249 shares Expires 2030-07-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	30,813	Not disclosed Strike: $10.75	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 20 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,813 shares Expires 2030-05-28 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F3 · derivative.exercise_date: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	4,542	Not disclosed Strike: $8.41	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 19 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,542 shares Expires 2030-04-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	2,851	Not disclosed Strike: $12.69	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 18 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,851 shares Expires 2030-01-02 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	4,025	Not disclosed Strike: $9.05	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 17 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,025 shares Expires 2029-10-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	2,846	Not disclosed Strike: $12.65	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 16 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,846 shares Expires 2029-07-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document
June 21, 2022 Filed Jun 24, 2022 01:46 UTC	R1 RCM Holdco Inc. NONE · Entity 125898	Disposition to issuerDirector Stock Option (right to buy) · Derivative	3,684	Not disclosed Strike: $9.57	Not disclosed	Disclosure SEC source: 0000899243-22-023862 · doc4.xml · derivative · entry 15 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,684 shares Expires 2029-04-01 F2 · shares: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F2 · price: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4 · derivative.exercise_date: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.